Ipamorelin (10mg) — Research Compound
Ipamorelin is a selective ghrelin receptor agonist and growth hormone secretagogue. Unlike earlier compounds in its class, Ipamorelin is studied for its high degree of selectivity, triggering growth hormone release without significantly affecting prolactin, cortisol, or ACTH levels. Researchers investigate Ipamorelin for its ability to mimic the pulsatile release of endogenous growth hormone and its subsequent impact on cellular repair, bone density, and lipid metabolism.
Findings from early-stage clinical trials have reported:
- Potent and pulsatile increases in plasma growth hormone levels observed following administration
- Improvements in gastric motility and the rate of gastric emptying reported in experimental models
- Enhanced bone mineral density and increased bone formation markers noted in-vivo
- Reductions in body fat percentage alongside the preservation of lean muscle mass reported in research studies
Researchers utilise Ipamorelin to study the regulation of the somatotropic axis and the physiological benefits of targeted growth hormone secretion. Its selective nature makes it an ideal tool for investigating long-term metabolic enhancements without the side effects associated with broader secretagogues. This makes it a primary focus for research into age-related growth hormone deficiency and recovery optimization.
Available Formats:
This compound is available in a 9ml premixed spray bottle, providing a stable solution for precise administration in research settings.
Used solely for in vitro experiments and cannot be:
- Used in clinical trials involving humans
- Administered to humans as part of an experiment or investigation
- Supplied to another party for human investigational use
| IDENTIFICATION | |
| Product Name | Ipamorelin 10 mg |
| Catalogue Number | RP-IPAMORELIN-01 |
| CAS Number | 170851-70-4 |
| Molecular Weight (g/mol) | 711.9 g/mol |
| Molecular Formula | C38H49N9O5 |
| Peptide Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| PHYSICAL AND CHEMICAL PROPERTIES | |
| Active Ingredient | Ipamorelin |
| Appearance | White to off-white lyophilised powder |
| Melting Point | Not applicable (decomposes before melting) |
| ANALYTICAL AND QUALITY CONTROL | |
| Mass Spectrum | Conforms to specification |
| Structural Confirmation | Consistent with theoretical structure / sequence |
| RESEARCH USE AND SAFETY | |
| Caution | Handle using appropriate PPE and in compliance with relevant laboratory safety standards. |
| Intended Use | For laboratory research use only. Not for human or veterinary use. |
| Hazard Classification | Not classified as hazardous under GHS for research quantities |
| STORAGE, HANDLING AND STABILITY | |
| Storage Temperature, Opened | -20 °C, minimise freeze–thaw cycles |
| Storage Temperature, Unopened | -20 °C recommended for long-term storage |
| Shelf Life | 2 years unopened under recommended conditions |
| Reconstitution Stability | Stable for up to 28 days at 2–8 °C in aqueous solution under sterile conditions |
Certificate of Analysis – Ipamorelin (99% Purity Verified)
| COMPOUND IDENTIFICATION | |
| Product Name | Ipamorelin (10mg Spray) |
| Batch / Reference ID | IP100309 |
| Sample Form | White powder in glass vial |
| ANALYTICAL RESULTS | |
| Chemical Purity | 99% (Verified) |
| Measured Content | 10.88mg (± 0.05mg) |
| Test Method | HPLC (High-Performance Liquid Chromatography) |
| LABORATORY TESTING INFORMATION | |
| Analysis Period | 28 Apr 2026 – 30 Apr 2026 |
| Laboratory Order # | 100014202 |
| QUALITY ASSURANCE | |
| Quality Testing Standards | All River Peptides products undergo batch-level laboratory analysis to verify compound identity and confirm purity levels. Learn more on our Quality Testing & Purity Verification page. |


